Prot #PCYC-1301-RA: A Randomized, Double-blind, Placebo-controlled Phase 1 Study of the Orally-administered Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-45466 with a Single Ascending Dose Phase in Healthy Subjects and a Multiple Ascending Dose Phase in Su

Project: Research project

Project Details

StatusFinished
Effective start/end date6/2/14 → 6/2/17

Funding

  • Pharmacyclics, Inc. (Prot #PCYC-1301-RA)